- Home
- CYH vs PLRX Comparison
CYH vs PLRX Comparison
Compare CYH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- PLRX
- Stock Information
- Founded
- CYH 1985
- PLRX 2015
- Country
- CYH United States
- PLRX United States
- Employees
- CYH N/A
- PLRX N/A
- Industry
- CYH Hospital/Nursing Management
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- PLRX Health Care
- Exchange
- CYH Nasdaq
- PLRX Nasdaq
- Market Cap
- CYH 623.8M
- PLRX 641.5M
- IPO Year
- CYH 1991
- PLRX 2020
- Fundamental
- Price
- CYH $3.07
- PLRX $11.21
- Analyst Decision
- CYH Hold
- PLRX Strong Buy
- Analyst Count
- CYH 6
- PLRX 7
- Target Price
- CYH $4.40
- PLRX $40.50
- AVG Volume (30 Days)
- CYH 2.3M
- PLRX 560.2K
- Earning Date
- CYH 02-18-2025
- PLRX 02-26-2025
- Dividend Yield
- CYH N/A
- PLRX N/A
- EPS Growth
- CYH N/A
- PLRX N/A
- EPS
- CYH N/A
- PLRX N/A
- Revenue
- CYH $12,551,000,000.00
- PLRX N/A
- Revenue This Year
- CYH $1.16
- PLRX N/A
- Revenue Next Year
- CYH $1.18
- PLRX N/A
- P/E Ratio
- CYH N/A
- PLRX N/A
- Revenue Growth
- CYH 0.81
- PLRX N/A
- 52 Week Low
- CYH $2.51
- PLRX $10.22
- 52 Week High
- CYH $6.29
- PLRX $18.92
- Technical
- Relative Strength Index (RSI)
- CYH 42.41
- PLRX 37.19
- Support Level
- CYH $2.88
- PLRX $11.02
- Resistance Level
- CYH $3.04
- PLRX $12.70
- Average True Range (ATR)
- CYH 0.13
- PLRX 0.80
- MACD
- CYH 0.03
- PLRX -0.18
- Stochastic Oscillator
- CYH 67.19
- PLRX 8.21
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.